NASDAQ:PPCB Propanc Biopharma Q2 2026 Earnings Report $0.60 -0.03 (-4.17%) Closing price 04:00 PM EasternExtended Trading$0.58 -0.02 (-3.46%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Propanc Biopharma EPS ResultsActual EPS-$7.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APropanc Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APropanc Biopharma Announcement DetailsQuarterQ2 2026Date2/17/2026TimeDuring Market HoursConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Propanc Biopharma Earnings HeadlinesPropanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015September 22 at 8:30 AM | globenewswire.comPropanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.September 16, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 24 at 1:00 AM | Profits Run (Ad)PPCB Advances PRP Toward Phase 1b Study; Trial Start Planned For February 2027September 9, 2026 | rttnews.comPropanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027September 9, 2026 | globenewswire.comPropanc Biopharma Reports PRP Preclinical Pancreatic Cancer Data Showing Over 90% Tumor Growth InhibitionAugust 27, 2026 | finance.yahoo.comSee More Propanc Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Propanc Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Propanc Biopharma and other key companies, straight to your email. Email Address About Propanc BiopharmaPropanc Biopharma (NASDAQ:PPCB), Inc. is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis. Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers. The company has described PRP as a formulation intended to act on cancer stem cells and other tumor-related mechanisms; its development remains subject to clinical and regulatory evaluation. Propanc Biopharma was founded in Australia and has operated as a development-stage biotechnology company serving the global oncology market. The company is led by James Nathanielsz, who has served as chief executive officer and has been involved in advancing its proenzyme-based cancer program. Propanc’s activities have primarily consisted of research, preclinical development and clinical planning rather than commercialized pharmaceutical sales.View Propanc Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
